Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
about
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysisEffectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugsA systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugsThe hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionHepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionHepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?Emergence of Hepatitis C Virus Genotype 4: Phylogenetic Analysis Reveals Three Distinct Epidemiological ProfilesA comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysisA complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategiesDrug users in Amsterdam: are they still at risk for HIV?Hepatitis C avoidance in injection drug users: a typology of possible protective practicesChanges in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohortsHIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in KenyaCandidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunitiesPublic health and international drug policy.HCV co-infection in HIV positive population in British Columbia, Canada.Multilevel analysis of HIV related risk behaviors among heroin users in a low prevalence communityA national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.Psychiatric distress, risk behavior, and treatment enrollment among syringe exchange participantsModelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.How understanding and application of drug-related legal instruments affects harm reduction interventions in Cambodia: a qualitative study.Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study.Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, EstoniaEstimating the force of infection for HCV in injecting drug users using interval-censored data.Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years.Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment-a case register analysis.Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam.Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.A cross-sectional study of public attitudes towards safer drug use practices in British Columbia, CanadaFactors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventionsFactors responsible for mortality variation in the United States: A latent variable analysis.Benefits of concurrent syringe exchange and substance abuse treatment participation.Changes in blood-borne infection risk among injection drug users.Toward a comprehensive approach to HIV prevention for people who use drugs.Vulnerability to HIV infection among female drug users in Kathmandu Valley, Nepal: a cross-sectional studyHigh regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillanceIs the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study.
P2860
Q22242071-C74F57D4-4954-4660-A9A8-AA30FECEC551Q24186785-3889AF6F-E8A3-4A5A-BE02-DA4648ACC064Q24629455-949E0D1F-34BF-4A33-8CDF-25578F1FD9E6Q26801456-EB2116AA-CB5E-4662-8C6B-4105BD1DBCA0Q27014761-5E1FEE6B-A0B0-4F9D-9B5C-1A0653A8563BQ27488973-233CD526-6726-4954-88A5-569FDB703541Q27490460-83625280-51A2-4A59-9BDE-78B09B340EE2Q27860879-55551B0D-9388-4536-A4B9-61CBE62A937CQ28304793-31BCDECD-E4C6-43B6-BCA8-B99A96962C7BQ28483747-E4275000-11F0-48CE-ADCB-C4AEDF4E7779Q28488151-4048C1CC-8694-48ED-9FD9-D023B63C46E2Q28534592-E9D8E0DF-4B78-4E2E-A638-C7D38F3035A2Q28542085-8B86884B-B817-45AB-96A2-2BA9DFCA0D49Q28608358-EEFCF03B-E92C-4632-898D-D26C2253CF29Q30226978-67CF7459-F304-4A97-A0C5-86FA4AC8BA7CQ30377895-92B12F60-C91C-4276-94C7-9CC9007F520FQ30982000-9A0C9726-FF62-482C-A887-F0FBE5D590DAQ33444309-79E895F5-2342-44B7-B604-5F7A94735EBFQ33483115-EC17716C-AF54-4203-A0B0-DECBC5FEA67CQ33592665-F94E79F0-CA9B-4DAE-A8CC-203484CF1028Q33695524-59D57601-C286-4869-B475-33C9E13BE9EDQ33769960-E069B599-6EBF-40F9-8F3F-74E6B2C0D1DEQ33814537-7F6B0933-2E7B-4617-97EB-6EF7B0DA5959Q33903707-C792B92B-9DC7-465E-A84D-22FBF77C3429Q33947137-BF5FC148-2A24-4B93-8FA4-F05BE246A9A1Q34017213-E7770230-AD53-4E48-86CC-AACEEB25CC37Q34028058-A4399496-C16D-40BA-83E4-C9D9807C86A4Q34163291-2B7B3118-E29D-4663-B20C-239B39C74ED3Q34259367-C1222FDC-7E87-4ADC-8E1F-1CE714EFA8C7Q34264303-CE8B948F-C9A6-43C1-8165-D76D39844E0AQ34332039-52D762E2-D2AC-4A17-B2B2-14317F62F289Q34461322-AB284DBC-76F8-4075-9ECF-21AFBD3CAEFAQ34545139-6D032036-6861-4573-8BDB-03460211324CQ34546989-50D47AEA-CD73-4244-AB6F-4423F7A0FA0EQ34669393-F75A6542-4D44-482D-96CC-1C0B5C9E10DBQ34772870-80717127-6EE9-4D55-9149-ED0313D9B70FQ34781762-8AE2905F-4DA3-4078-9423-D4E86FC98C6AQ35077021-6D4FBD68-5C37-42F9-8910-F3AB14ECD9C3Q35120376-E02A3687-3972-49BA-8036-36C832F0B062Q35179898-ED4038D0-B029-40F4-AFC8-E64B02CA185B
P2860
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Full participation in harm red ...... hort Studies among drug users.
@ast
Full participation in harm red ...... hort Studies among drug users.
@en
type
label
Full participation in harm red ...... hort Studies among drug users.
@ast
Full participation in harm red ...... hort Studies among drug users.
@en
prefLabel
Full participation in harm red ...... hort Studies among drug users.
@ast
Full participation in harm red ...... hort Studies among drug users.
@en
P2093
P2860
P1433
P1476
Full participation in harm red ...... hort Studies among drug users.
@en
P2093
Amsterdam Cohort
Charlotte Van Den Berg
Colette Smit
Giel Van Brussel
Roel Coutinho
P2860
P304
P356
10.1111/J.1360-0443.2007.01912.X
P407
P50
P577
2007-09-01T00:00:00Z